With drug approval times taking an average of 8 years from entry into clinical trials to full U.S. Food and Drug Administration (FDA) approval, patients with life-threatening and severely debilitating disease and no reasonable therapeutic options are advocating for expanded access (EA) to investigational drugs prior to approval. Special investigational new drug (IND) application categories allow patients who meet specific criteria to receive treatment with non-approved drugs.
Recent federal legislation seeking to expedite drug deployment to patients may significantly affect how such therapeutics enter the FDA processes and how soon they reach the public. This article discusses the FDA process for individual patient access to nonapproved drugs, and explores "right-to-try" (R2T)
legislation that is intended to facilitate the entry of new therapeutics into clinical use prior to full FDA approval.
INVESTIGATIONAL NEW DRUG INDs
The basic IND filing is a request for FDA authorization A to administer a non-approved drug or biological product to humans so that evidence of efficacy and safety can be obtained for marketing approval. In addition, federal law requires that a drug be the subject of an approved marketing application before it can be transported or distributed across state lines. Long before FDA approval, the drug developer will usually want to ship the drug to clinical investigators in multiple states, and they must obtain an exemption from that law. The IND application provides the means by which a drug sponsor can acquire this exemption (4) . 
FDA EXPANDED ACCESS INDs FOR NONAPPROVED DRUGS
The FDA began facilitating access to non-approved drugs in the 1970s, although it took until 1987 for a specific pathway for such access to be developed (6 
clinical trials, in single patient use, the treating physician must usually obtain a separate IND.
Obtaining an individual patient IND, follows similar steps, whether in an emergency or not ( Figure 1) prospective IRB approval can be waived. In order to so, however, conditions for waiver must meet all of the requirements described in FDA regulations for "life-threatening" or "severely debilitating" condition ( Table 1) . Any "subsequent use" of the drug after initial emergency treatment is subject to prospective IRB review and approval. The FDA defines "use" and "subsequent use" as either a single dose, or a single course of treatment (16) . If the investigator anticipates a second course of treatment, IRB review is required, however the FDA also states that "in spite of the best efforts of the clinical investigator and the IRB," the need may arise for a second emergency use.
The FDA states that it believes "it is inappropriate to deny emergency treatment to an individual when the only obstacle is lack of time for the IRB to convene, review the use and give approval" (16). When prospective IRB review is waived by the FDA in an EIND, investigator must file a full report with the institutional IRB no more than 5 days after use of the drug. Applicants should take note of the fact that the FDA does not accept an IRB "approval" that is anything less than full IRB approval, even in an emergency. This means that "interim", "compassionate", "temporary" or other terms for any local "expedited" IRB approval process will not be accepted as "IRB approval". Rather, the FDA explicitly states that "An IRB must either convene and give Shipping and use of the drug occurs in that case before actual FDA receipt of the written application (which must be received by the FDA in no case more than 15 working days after initiation of the EIND by phone or other method) (7, 22) , and the institutional IRB must be notified within 5 days of administration of the drug (7). Van Norman
evaluation from an independent physician within 5 days of use of the drug, and notify the IRB that this has been done.
Informed consent can be waived in planned research in life-threatening situations in which the subjects will not generally be able to consent. However, the research plan and waiver of consent must be approved in advance by the FDA and the institutional IRB as part of the research protocol (23). 
ACCESSING INVESTIGATIONAL DRUGS
WITHOUT THE FDA: "RIGHT-TO-TRY"
LEGISLATION
The plight of patients seeking access to unapproved treatment has been heavily covered in the media (25, 26) , and even forms the basis of a Hollywood movie, the Dallas Buyers Club (27) . R2T has also been both publicized and heavily supported by political organizations that concentrate on states' rights, such as the Goldwater Institute, a libertarian think tank (28) . In addition, the use by patients of social media and multimedia formats to petition drug companies for access to investigational drugs has been on the rise (29) .
Unfortunately, both the public debate surrounding The FDA approves over 99% of all SP IND requests, whether non-emergent or emer-
Single Patient IND (6, 23, 30 requests were denied or not allowed to proceed (22) .
Despite the high approval rate, however, the FDA is not merely "rubber stamping" these requests, but
serves an important review function, as reasons for the denials demonstrate. The most common reason for denial of the EIND was that the patient was already stable on current therapy and thus the situation was not deemed to be an emergency. Of the 24 nonemergent single-patient INDs that were not allowed, the most common reasons were incomplete application (usually a lack of a LOA from the manufacturer), unsafe dosing, proven lack of efficacy for intended use, availability of adequate alternative therapies, and insufficient information provided by the applicant on which to base a decision (22) . Companies are not required by law to provide investigational drugs upon request, and thus far, no pharmaceutical company has guaranteed that they will make drugs available under the legislation.
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In fact, some pharmaceutical companies actively oppose the measure. Merck and Co has stated, "While well-intentioned, current R2T legislation is not in the best interest of patients and is unlikely to help us bring forward innovative, safe and effective medicines to all patients as quickly as possible" (45) .
Although the former CEO of Neuralstem, Inc. testified in favor of the bill, he appears to be alone among pharmaceutical executives: even his own company management opposed it, feeling it would 'delay or jeopardize the approval of therapies by reducing the supply of study agents or adversely affecting the data collection process' (45, 46) . Pfizer and Eli Lilly commit to respond to such requests in no more than 5 days after receiving the required documentation (48, 50) . Lycera promises a response within 3 to 5 "business days" (51) . In the case of some specific therapeutics, such as Catalyst Pharma's therapeutic, amifampridine phosphate, for Lambert-Eaton syndrome, the response may take up to 30 days (52).
Although companies have developed internal pathways by which individual patients can achieve access to investigational drugs, the majority of such requests are denied. In 2015, Janssen, after consultation with the Division of Medical Ethics at NYU Langone Medical Center, developed a 10-person committee to review requests for compassionate use of its investigational drug daratumumab. In the last 6 months of 2015, they received 160 requests, of which they approved only 62 (13) .
OBTAINING ACCESS TO DRUGS UNDER R2T
The steps to obtaining an investigational drug from the manufacturer under R2T are less clear than 
CONCERNS ABOUT R2T
While it is hard not to empathetically side with the plaintiffs in Abigail, bypassing the FDA approval process is fraught with risks, both for the general public, and for patients seeking desperate therapies , and yet failure rates for drugs (e.g., 90% failure for anticancer drugs reaching phase I trials) (1, 53) suggests that there is actually little reason to assume that most patients would benefit from receiving drugs in their earliest stages of development, and much more substantial reason to anticipate that many patients would be harmed.
C r e a t i o n o f a " g u i n e a p i g c l a s s " o f p a t i e n t s . The opening of the market to sale of investigational drugs raises the specter of creating a 2-tiered treatment system, with the wealthiest payers able to pay for and access expensive treatments ahead of approval, and poor patients relegated to only having access if they agree to become the "guinea pigs" of clinical trials.
The ability of some patients to pay for drug access may reduce also the number of patients available for clinical trials, slowing progress towards full drug approval.
P a t i e n t b e n e fi t s a n d h a r m s . The likelihood that an investigational drug that is early in clinical phase testing will be beneficial and not harmful is actually quite small. Only about 10% of drugs completing
Phase I testing will eventually be approved, and the most common reasons they fail in clinical trials are proven lack of efficacy and/or problems with drug safety (1, 32) . Harms to patients from untested or incompletely tested therapies can be considerable: an historical example was high-dose chemotherapy and bone marrow transplant for advanced breast cancer, which physicians were so convinced was effective therapy that clinical trials were delayed for years.
Clinical studies eventually proved that the therapy was ineffective, but not before countless women were harmed, and dozens died as a direct result of treatment toxicity (32) . Van Norman C h a r g i n g t h e p a t i e n t . Both the FDA and R2T legislation allow the manufacturer to charge for the drug (55) . In the case of the FDA, charges must be approved, but can include not only the direct costs, handling and shipping charges, but in some cases monitoring and reporting costs. Even so, the charge for investigational drugs is likely to be less than the drug charge will be if full FDA approval is achieved Table 4 . FDA EIND eligibility is broader than that for R2T, encompassing both "serious" and "immediately life-threatening" disease, rather than being limited to terminal disease. 
CONCLUSIONS
Once a drug enters clinical trials, it takes an average of 8 years to achieve market approval, and over 90% 
